Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors

    Cancer Categories
    • Breast,Gynecologic
    Karmanos Trial ID
    • 2023-080
    NCT ID
    • NCT05787587
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I
    Principal Investigator

    Objective:

    Primary Objectives:

    • Part 1 (Dose Escalation): To characterize the
      safety and tolerability of IDE161 monotherapy to
      determine the MTD/MAD, and/or RDE
    • Part 2 (Dose Expansion): To further assess the
      safety and tolerability of IDE161 monotherapy at
      the RDE
    • Part 2: To evaluate preliminary anti-tumor
      activity of IDE161 monotherapy

    Secondary Objectives:

    • Part 1: To evaluate preliminary anti-tumor
      activity of IDE161 monotherapy
    • Part 2: Assess risk/benefit at an IDE161
      monotherapy dose and exposure alternative to
      the initial expansion dose
    • Both parts: To characterize the single and
      multiple dose PK of IDE161 monotherapy
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266